metformin has been researched along with Abdominal Pain in 13 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin-associated lactic acidosis (MALA) is a rare complication among patients who are diabetic, commonly presenting with non-specific findings, and developing mostly among those with other risk factors for lactic acidosis." | 7.88 | Metformin-associated lactic acidosis mimicking ischaemic bowel. ( Ali, S; Azarov, N; Hindi, Z; Labuschagne, H; Oud, L, 2018) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 7.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 6.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| " In these studies, metformin use was associated with higher risk of abdominal pain, diarrhea and nausea comparing to control." | 5.22 | Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. ( Gumprecht, J; Hendel, M; Irlik, K; Januszkiewicz, K; Kwiendacz, H; Lip, GYH; Nabrdalik, K; Skonieczna-Żydecka, K; Łoniewski, I, 2022) |
| "Metformin-associated lactic acidosis (MALA) is a rare complication among patients who are diabetic, commonly presenting with non-specific findings, and developing mostly among those with other risk factors for lactic acidosis." | 3.88 | Metformin-associated lactic acidosis mimicking ischaemic bowel. ( Ali, S; Azarov, N; Hindi, Z; Labuschagne, H; Oud, L, 2018) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 3.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "Lactic acidosis is a rare, serious adverse effect of metformin, which can be prevented by carefully observing the contra-indications." | 2.41 | [Metformin efficacious in poorly controlled diabetes mellitus type 2]. ( Hoekstra, JB; Holleman, F; Stades, AM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Mehrpour, O | 1 |
| Saeedi, F | 1 |
| Hoyte, C | 1 |
| Hadianfar, A | 1 |
| Nakhaee, S | 1 |
| Brent, J | 1 |
| Nabrdalik, K | 2 |
| Skonieczna-Żydecka, K | 2 |
| Irlik, K | 1 |
| Hendel, M | 1 |
| Kwiendacz, H | 2 |
| Łoniewski, I | 2 |
| Januszkiewicz, K | 1 |
| Gumprecht, J | 2 |
| Lip, GYH | 1 |
| Drożdż, K | 1 |
| Kaczmarczyk, M | 1 |
| Wijata, AM | 1 |
| Nalepa, J | 1 |
| Holleman, F | 2 |
| Nieuwdorp, M | 1 |
| Ali, S | 1 |
| Labuschagne, H | 1 |
| Azarov, N | 1 |
| Hindi, Z | 1 |
| Oud, L | 1 |
| Schuenemeyer, JW | 1 |
| Jette-Kelly, LA | 1 |
| Kalantar-Zadeh, K | 1 |
| Uppot, RN | 1 |
| Lewandrowski, KB | 1 |
| Unwin, D | 1 |
| Tobin, S | 1 |
| Bundrick, JB | 1 |
| Litin, SC | 1 |
| Khattab, S | 1 |
| Mohsen, IA | 1 |
| Aboul Foutouh, I | 1 |
| Ashmawi, HS | 1 |
| Mohsen, MN | 1 |
| van Wely, M | 1 |
| van der Veen, F | 1 |
| Youssef, MA | 1 |
| Parke, C | 1 |
| Lien, YH | 1 |
| Yang, W | 1 |
| Guan, Y | 1 |
| Shentu, Y | 1 |
| Li, Z | 1 |
| Johnson-Levonas, AO | 1 |
| Engel, SS | 1 |
| Kaufman, KD | 1 |
| Goldstein, BJ | 1 |
| Alba, M | 1 |
| Quint, EH | 1 |
| Stades, AM | 1 |
| Hoekstra, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy[NCT00813995] | Phase 3 | 395 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin | -43.4 |
| Placebo | -10.0 |
Change from baseline at Week 24 is defined as Week 24 minus Week 0. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Sitagliptin | -20.3 |
| Placebo | 0.5 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -1.02 |
| Placebo | -0.14 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -0.84 |
| Placebo | -0.01 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. (NCT00813995)
Timeframe: Baseline and Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Sitagliptin | -1.14 |
| Placebo | -0.21 |
2 reviews available for metformin and Abdominal Pain
| Article | Year |
|---|---|
Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials.
Topics: Abdominal Pain; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycem | 2022 |
[Metformin efficacious in poorly controlled diabetes mellitus type 2].
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Blood Glucose; Contraindications; Diabetes Mellitus; Diabete | 2000 |
2 trials available for metformin and Abdominal Pain
| Article | Year |
|---|---|
Clinical Trial: Probiotics in Metformin Intolerant Patients with Type 2 Diabetes (ProGasMet).
Topics: Abdominal Pain; Diabetes Mellitus, Type 2; Diarrhea; Double-Blind Method; Humans; Metformin; Polyest | 2023 |
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea | 2012 |
9 other studies available for metformin and Abdominal Pain
| Article | Year |
|---|---|
Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States.
Topics: Abdominal Pain; Acidosis; Adolescent; Adult; Aged; Child; Creatinine; Diabetes Mellitus; Diarrhea; D | 2022 |
Metformin-associated lactic acidosis mimicking ischaemic bowel.
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Diabetes Mellitus; Diagnosis, Differential; Emergency Medica | 2018 |
A 35-Year-Old Woman With Shock, Pulseless Electrical Activity Arrest, and Hemodynamic Collapse.
Topics: Abdominal Pain; Acidosis, Lactic; Adult; Diabetes Mellitus, Type 2; Diagnosis, Differential; Drug-Re | 2019 |
Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion.
Topics: Abdominal Pain; Acidosis, Lactic; Confusion; Diabetes Mellitus, Type 2; Diagnosis, Differential; Fem | 2013 |
A patient request for some "deprescribing".
Topics: Abdominal Pain; Diabetes Mellitus, Type 2; gamma-Glutamyltransferase; Humans; Hypoglycemic Agents; L | 2015 |
Clinical pearls in general internal medicine.
Topics: Abdominal Pain; Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Androgen Antagonists; Anti-Inf | 2011 |
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
Topics: Abdominal Pain; Adult; Cohort Studies; Diabetes, Gestational; Egypt; Female; Fertilization in Vitro; | 2011 |
Quiz page June 2011. Profound metabolic acidosis and abdominal pain in a diabetic patient on long-term hemodialysis.
Topics: Abdominal Pain; Acidosis, Lactic; Diabetic Nephropathies; Diagnosis, Differential; Follow-Up Studies | 2011 |
Hirsutism and adnexal masses in a teenager.
Topics: Abdominal Pain; Adolescent; Contraceptives, Oral, Combined; Diagnosis, Differential; Female; Hirsuti | 2002 |